Immunomodulation using the recombinant monoclonal human B7-DC cross-linking antibody rHIgM12

V. P. Van Keulen, B. Ciric, S. Radhakrishnan, K. L. Heckman, Y. Mitsunaga, K. Iijima, Hirohito Kita, M. Rodriguez, Larry R Pease

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

A patient with Waldenstrom's macroglobulinaemia expresses a high titre IgM antibody in serum that binds both mouse and human dendritic cells (DC) in a B7-DC (PD-L2)-dependent manner. We have reported previously that purified antibody from patient serum activates immature and mature DC in vitro, enhancing the ability of these professional antigen-presenting cells to activate naive T cells, take up antigen, resist a cytokine-depleted environment and secrete immunomodulatory cytokines, such as interkeukin (IL)-6 and tumour necrosis factor (TNF)-α. Systemic treatment of experimental animals with this antibody induces potent anti-melanoma immunity and modulates protectively the recall response against antigen challenge through the airway in an experimental model of inflammatory airway disease. Here we describe a monoclonal IgM antibody derived from this serum immunoglobulin that recapitulates each of these earlier observations, providing direct evidence that M protein from the Waldenstrom's patient mediates these potent immunomodulatory effects. Furthermore, cell lines expressing this recombinant form of the human antibody provide the basis for developing this reagent for clinical application.

Original languageEnglish (US)
Pages (from-to)314-321
Number of pages8
JournalClinical and Experimental Immunology
Volume143
Issue number2
DOIs
StatePublished - Feb 2006

Fingerprint

Immunomodulation
Dendritic Cells
Antibodies
Immunoglobulin M
Serum
Cytokines
Antigens
Waldenstrom Macroglobulinemia
Antigen-Presenting Cells
Immunoglobulins
Immunity
Melanoma
Interleukin-6
Theoretical Models
Tumor Necrosis Factor-alpha
Monoclonal Antibodies
T-Lymphocytes
Cell Line
Proteins
Therapeutics

Keywords

  • Allergy
  • Cancer
  • Dendritic cells
  • Therapy/immunotherapy

ASJC Scopus subject areas

  • Immunology

Cite this

Immunomodulation using the recombinant monoclonal human B7-DC cross-linking antibody rHIgM12. / Van Keulen, V. P.; Ciric, B.; Radhakrishnan, S.; Heckman, K. L.; Mitsunaga, Y.; Iijima, K.; Kita, Hirohito; Rodriguez, M.; Pease, Larry R.

In: Clinical and Experimental Immunology, Vol. 143, No. 2, 02.2006, p. 314-321.

Research output: Contribution to journalArticle

Van Keulen, VP, Ciric, B, Radhakrishnan, S, Heckman, KL, Mitsunaga, Y, Iijima, K, Kita, H, Rodriguez, M & Pease, LR 2006, 'Immunomodulation using the recombinant monoclonal human B7-DC cross-linking antibody rHIgM12', Clinical and Experimental Immunology, vol. 143, no. 2, pp. 314-321. https://doi.org/10.1111/j.1365-2249.2005.02992.x
Van Keulen, V. P. ; Ciric, B. ; Radhakrishnan, S. ; Heckman, K. L. ; Mitsunaga, Y. ; Iijima, K. ; Kita, Hirohito ; Rodriguez, M. ; Pease, Larry R. / Immunomodulation using the recombinant monoclonal human B7-DC cross-linking antibody rHIgM12. In: Clinical and Experimental Immunology. 2006 ; Vol. 143, No. 2. pp. 314-321.
@article{96d4cfab06ce4f1084664b413de36d53,
title = "Immunomodulation using the recombinant monoclonal human B7-DC cross-linking antibody rHIgM12",
abstract = "A patient with Waldenstrom's macroglobulinaemia expresses a high titre IgM antibody in serum that binds both mouse and human dendritic cells (DC) in a B7-DC (PD-L2)-dependent manner. We have reported previously that purified antibody from patient serum activates immature and mature DC in vitro, enhancing the ability of these professional antigen-presenting cells to activate naive T cells, take up antigen, resist a cytokine-depleted environment and secrete immunomodulatory cytokines, such as interkeukin (IL)-6 and tumour necrosis factor (TNF)-α. Systemic treatment of experimental animals with this antibody induces potent anti-melanoma immunity and modulates protectively the recall response against antigen challenge through the airway in an experimental model of inflammatory airway disease. Here we describe a monoclonal IgM antibody derived from this serum immunoglobulin that recapitulates each of these earlier observations, providing direct evidence that M protein from the Waldenstrom's patient mediates these potent immunomodulatory effects. Furthermore, cell lines expressing this recombinant form of the human antibody provide the basis for developing this reagent for clinical application.",
keywords = "Allergy, Cancer, Dendritic cells, Therapy/immunotherapy",
author = "{Van Keulen}, {V. P.} and B. Ciric and S. Radhakrishnan and Heckman, {K. L.} and Y. Mitsunaga and K. Iijima and Hirohito Kita and M. Rodriguez and Pease, {Larry R}",
year = "2006",
month = "2",
doi = "10.1111/j.1365-2249.2005.02992.x",
language = "English (US)",
volume = "143",
pages = "314--321",
journal = "Clinical and Experimental Immunology",
issn = "0009-9104",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Immunomodulation using the recombinant monoclonal human B7-DC cross-linking antibody rHIgM12

AU - Van Keulen, V. P.

AU - Ciric, B.

AU - Radhakrishnan, S.

AU - Heckman, K. L.

AU - Mitsunaga, Y.

AU - Iijima, K.

AU - Kita, Hirohito

AU - Rodriguez, M.

AU - Pease, Larry R

PY - 2006/2

Y1 - 2006/2

N2 - A patient with Waldenstrom's macroglobulinaemia expresses a high titre IgM antibody in serum that binds both mouse and human dendritic cells (DC) in a B7-DC (PD-L2)-dependent manner. We have reported previously that purified antibody from patient serum activates immature and mature DC in vitro, enhancing the ability of these professional antigen-presenting cells to activate naive T cells, take up antigen, resist a cytokine-depleted environment and secrete immunomodulatory cytokines, such as interkeukin (IL)-6 and tumour necrosis factor (TNF)-α. Systemic treatment of experimental animals with this antibody induces potent anti-melanoma immunity and modulates protectively the recall response against antigen challenge through the airway in an experimental model of inflammatory airway disease. Here we describe a monoclonal IgM antibody derived from this serum immunoglobulin that recapitulates each of these earlier observations, providing direct evidence that M protein from the Waldenstrom's patient mediates these potent immunomodulatory effects. Furthermore, cell lines expressing this recombinant form of the human antibody provide the basis for developing this reagent for clinical application.

AB - A patient with Waldenstrom's macroglobulinaemia expresses a high titre IgM antibody in serum that binds both mouse and human dendritic cells (DC) in a B7-DC (PD-L2)-dependent manner. We have reported previously that purified antibody from patient serum activates immature and mature DC in vitro, enhancing the ability of these professional antigen-presenting cells to activate naive T cells, take up antigen, resist a cytokine-depleted environment and secrete immunomodulatory cytokines, such as interkeukin (IL)-6 and tumour necrosis factor (TNF)-α. Systemic treatment of experimental animals with this antibody induces potent anti-melanoma immunity and modulates protectively the recall response against antigen challenge through the airway in an experimental model of inflammatory airway disease. Here we describe a monoclonal IgM antibody derived from this serum immunoglobulin that recapitulates each of these earlier observations, providing direct evidence that M protein from the Waldenstrom's patient mediates these potent immunomodulatory effects. Furthermore, cell lines expressing this recombinant form of the human antibody provide the basis for developing this reagent for clinical application.

KW - Allergy

KW - Cancer

KW - Dendritic cells

KW - Therapy/immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=33644853625&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644853625&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2249.2005.02992.x

DO - 10.1111/j.1365-2249.2005.02992.x

M3 - Article

C2 - 16412056

AN - SCOPUS:33644853625

VL - 143

SP - 314

EP - 321

JO - Clinical and Experimental Immunology

JF - Clinical and Experimental Immunology

SN - 0009-9104

IS - 2

ER -